| I-11 Linda Franken Pharmacokinetics of midazolam and its metabolites in terminally ill adult patients Wednesday 10:20-11:40 |
| I-17 Peter Gennemark Unravelling the pharmacokinetic interaction of ticagrelor and MEDI2452 (ticagrelor-antidote) using mouse data Wednesday 10:20-11:40 |
| I-22 Anais Glatard Influence of UGT2B7 polymorphism on varenicline clearance in a cohort of smokers from the general population Wednesday 10:20-11:40 |
| I-24 Bojana Golubovic Population modelling of sirolimus data available from routine therapeutic drug monitoring Wednesday 10:20-11:40 |
| I-34 Janelle Hajjar Modeling Duchenne muscular dystrophy disease progression as assessed by the 6-minute walk test Wednesday 10:20-11:40 |
| I-35 Nayoung Han Dose estimation based on population pharmacokinetic/pharmacogenetic modeling for enteric-coated mycophenolate sodium in kidney transplant recipients Wednesday 10:20-11:40 |
| I-38 Paul Healy Model-based dose selection of tocilizumab for the prevention of reperfusion injury. Wednesday 10:20-11:40 |
| I-39 Michael Heathman A Categorical Time Course PKPD Model Describing the Effect of Ixekizumab on Improvement from Baseline in Psoriasis Area and Severity Index (PASI) score in Patients with Moderate to Severe Plaque Psoriasis Wednesday 10:20-11:40 |
| I-48 Manuel Ibarra Pharmacokinetic characterization of naphtalophos in lambs by modelling blood acetylcholinesterase activity, a K-PD model Wednesday 10:20-11:40 |
| II-01 Khaled Abduljalil Simcyp Simulator within the DDMoRe Interoperability Framework – Proof of Concept Cases Wednesday 15:10-16:30 |
| II-02 João Abrantes Population pharmacokinetic analysis of factor VIII activity following treatment with moroctocog alfa in moderate to severe haemophilia A subjects Wednesday 15:10-16:30 |
| II-14 Violeta Balbas-Martinez Target evaluation for Inflammatory Bowel Disease (IBD) using a Systems Pharmacology model Wednesday 15:10-16:30 |
| II-25 Charlotte Bon A target mediated cellular uptake model to assess the asialogycoprotein receptor shuttle capacity in hepatocytes Wednesday 15:10-16:30 |
| II-37 Luzelena Caro Population Pharmacokinetics Modeling Characterizes the Higher Grazoprevir Exposure in Japanese Compared to Non-Japanese HCV-Infected Patients Wednesday 15:10-16:30 |
| II-39 Jason Cawley Competitive brain and body growth model Wednesday 15:10-16:30 |
| II-46 Maxwell Chirehwa Semi-mechanistic pharmacokinetic model for Isoniazid and Acetyl isoniazid in a cohort of TB/HIV co-infected patients Wednesday 15:10-16:30 |
| II-51 Pieter Colin Propofol breath monitoring as a potential tool to improve the prediction of intraoperative plasma concentrations Wednesday 15:10-16:30 |
| II-65 Wilbert de Witte High drug-target association rates increase the duration of in vivo target occupancy Wednesday 15:10-16:30 |
| II-70 Christiane Dings Pharmacokinetic and Pharmacodynamic Modeling of Acetylsalicylic Acid and its Major Metabolite Salicylic Acid Wednesday 15:10-16:30 |
| II-74 Erwin Dreesen Anti-drug antibodies, low serum albumin and high C-reactive protein increase infliximab clearance in patients with inflammatory bowel disease: a population pharmacokinetic study of the TAXIT trial Wednesday 15:10-16:30 |
| II-77 Vincent Dubois Joint modelling of pain intensity and informative dropout in moderate to severe chronic pain patients Wednesday 15:10-16:30 |
| III-02 Lia Liefaard Mixed effects modelling of dose-response cough count data Thursday 10:05-11:30 |
| III-04 Ling Xue Theory based PK-PD of S- and R-warfarin: influence of body size, composition and genotype Thursday 10:05-11:30 |
| III-11 Mats Magnusson Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis Thursday 10:05-11:30 |
| III-14 Vikash Mansinghka BayesDB Marcro Indicator Explorer ensemble models for growth outcome country phenotyping Thursday 10:05-11:30 |
| III-19 Jean-Marie Martinez Modelling and simulation of alirocumab – Part 1: Population pharmacokinetic analysis using a Michaelis-Menten approximation of the target-mediated drug disposition model Thursday 10:05-11:30 |
| III-26 Pablo Morentin Gutierrez A population pharmacokinetic-pharmacodynamic model for AZD7687: Effects on plasma triacylglycerol after oral lipid tolerance test Thursday 10:05-11:30 |
| III-30 Zufar Muliukov Modeling the effect of ranibizumab on central retinal thickness in patients with wet age-related macular degeneration Thursday 10:05-11:30 |
| III-34 Xavier Nicolas Modelling and simulation of alirocumab - Part 2: Population pharmacokinetic/pharmacodynamic analysis using an indirect response model to link drug concentrations with LDL-C Thursday 10:05-11:30 |
| III-35 Jaeseong Oh Simultaneous population pharmacokinetic analysis of VVZ-149 and its active metabolite in healthy volunteers Thursday 10:05-11:30 |
| III-36 Boram Ohk Population Pharmacokinetic modeling of Tacrolimus in Healthy Korean Subjects Thursday 10:05-11:30 |
| III-42 - - Delineation of the treatment effect of methotrexate when used in combination therapy for rheumatoid arthritis Thursday 10:05-11:30 |
| III-52 Tatiana Petukhova Population PK modeling of RPH-104, novel optimized IL-1 beta trap, and assessment of the immunogenicity effect on pharmacokinetics Thursday 10:05-11:30 |
| III-55 Chiara Piana A novel model-based methodology for the evaluation of abuse potential Thursday 10:05-11:30 |
| III-65 Isabel Reinecke Changes in endogenous estradiol concentrations explain fluctuations in levonorgestrel (LNG) concentrations during continuous treatment with LNG releasing intravaginal rings Thursday 10:05-11:30 |
| III-68 Jakob Ribbing Predicting reductions in chronic obstructive pulmonary disease (COPD) exacerbations from FEV1 – A model-based meta-analysis of literature data from controlled randomized clinical trials Thursday 10:05-11:30 |
| III-69 Camille Riff First population pharmacokinetic model of lidocaine tumescent anaesthesia in women undergoing breast cancer surgery Thursday 10:05-11:30 |
| III-72 Stefan Roepcke Model-based analysis of monkey PK and PD data of a therapeutic cell depleting human monoclonal antibody – Preparing for clinical trials Thursday 10:05-11:30 |
| IV-04 Nina Scherer Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9 Thursday 14:40-16:00 |
| IV-11 Victor Sokolov A mechanistic PKPD model relating early asthmatic response to anti-leukotriene drug PK and biomarker levels in allergen challenge studies Thursday 14:40-16:00 |
| IV-14 Konstantina Soulele A population pharmacokinetic study of salmeterol in asthmatic patients using two dry powder inhalers Thursday 14:40-16:00 |
| IV-18 Siddharth Sukumaran A quantitative systems pharmacology model for evaluating potential drugs for treatment of asthma Thursday 14:40-16:00 |
| IV-22 Tatiana Yakovleva A systems pharmacology model of SGLT2 and SGLT1 inhibition to understand mechanism and quantification of urinary glucose excretion after treatment with Dapagliflozin, Canagliflozin and Empagliflozin Thursday 14:40-16:00 |
| IV-25 Adrien Tessier Population Pharmacokinetic modelling and Pharmacogenetic analysis through a penalised regression approach for a molecule S Thursday 14:40-16:00 |
| IV-47 Coen van Hasselt The proof is in the pee: Population asparagus urinary odor kinetics. Thursday 14:40-16:00 |
| IV-51 Camille Vong Population Pharmacokinetics of Tofacitinib in Induction Studies for Moderate-to-Severe Ulcerative Colitis Patients Thursday 14:40-16:00 |
| IV-59 Thomas Wendl Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients Thursday 14:40-16:00 |
| IV-65 Dan Wright A population pharmacokinetic model for 51Cr EDTA, an isotopic biomarker for renal function: impact on carboplatin dosing. Thursday 14:40-16:00 |
| IV-68 Younghoon Yoo Pharmacokinetic Model for subconjunctival injection of bevacizumab in Rabbits. Thursday 14:40-16:00 |
| IV-72 Fan Zhang Population pharmacokinetic modeling of lamotrigine in Chinese subjects Thursday 14:40-16:00 |
| IV-77 Kirill Zhudenkov A Markov Chain model to characterize cataract progression and disease burden in the Russian Federation Thursday 14:40-16:00 |
